NB3:F:F-Neurocrine Biosciences Inc (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 131.4

Change

+2.90 (+2.26)%

Market Cap

USD 13.12B

Volume

15.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 72.39B
MRK:F Merck & Company Inc

+2.50 (+1.46%)

USD 72.39B
ZOE:F Zoetis Inc

-3.40 (-2.05%)

USD 71.43B
TKD:F Takeda Pharmaceutical Company ..

-0.04 (-0.16%)

USD 38.51B
TKDA:F Takeda Pharmaceutical Company ..

-0.10 (-0.81%)

USD 38.51B
H6D0:F Haleon PLC

+0.03 (+0.66%)

USD 35.07B
H6D:F Haleon PLC

-0.05 (-0.66%)

USD 34.89B
TEV:F Teva Pharmaceutical Industries..

+0.05 (+0.31%)

USD 17.38B
3KY:F HANSOH PHARMAC. HD-00001

+0.02 (+0.99%)

USD 13.01B
SH0:F Shionogi & Co. Ltd

N/A

USD 11.74B

ETFs Containing NB3:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.56% 53% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.56% 49% F 60% D-
Trailing 12 Months  
Capital Gain 50.62% 86% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.62% 80% B- 82% B
Trailing 5 Years  
Capital Gain 85.86% 88% B+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.86% 65% D 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 8.01% 83% B 71% C-
Dividend Return 8.01% 77% C+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.71% 61% D- 50% F
Risk Adjusted Return 33.78% 75% C 63% D
Market Capitalization 13.12B 96% N/A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.